Opinion
Video
Author(s):
Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.
Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer
Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer
Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation
Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma
CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL
Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL
Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera